Home to pioneering researchers at the forefront of making groundbreaking discoveries, OHSU is able to offer patients the best in care with access to the most innovated and advanced clinical trials. As leaders in the field of cancer research, the department of urology works hand in hand with the Knight Cancer Institute and multiple other specialties to bring the best of new treatments to the fight against bladder, prostate, and kidney cancers. Discover the opportunities in OHSU's clinical trials that lead to exciting, tangible breakthroughs in disease treatment.
|PI Name||Protocol #||Title|
|Jen-Jane Liu||STUDY00023919||Clinical Performance Evaluation of the C2i-WGS-MRD Test for detecting molecular residual disease (MRD) in bladder cancer patients|
|Jason Hedges||STUDY00024016||"AN OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, THREE TREATMENT ARM, MULTICENTER STUDY ON HYPOGONADAL MALES TO EVALUATE THE EFFECT ON 24-HOUR AMBULATORY BLOOD PRESSURE AFTER 16-WEEK CONTINUOUS TREATMENT WITH MARKETED TESTOSTERONE PRODUCTS"|
|Jason Hedges||A MULTI-CENTER, RANDOMIZED, BLINDED, CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF THE UROCROSS™ EXPANDER SYSTEM AND RETRIEVAL SHEATH (EXPANDER-2)”|
|Ian Metzler||STUDY0024375||Evaluation of Applaud Medical’s Acoustic Enhancer with Laser Lithotripsy System in the Treatment of Urinary Stones (aka AEROLITH Clinical Study (USA)) according to the Protocol, as defined below (the “Trial”)|
|Jen-Jane Liu||Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG Naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC).|
|Jen-Jane Liu||enGene Phase I/II NMIBC study A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive NMIBC and High-Risk NMIBC Patients who are BCG Naive or Received Incomplete BCG Treatment|
|Casey Seideman||A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)|
|Sudhir Isharwal||STUDY00022150||A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions|
|Jason Hedges||STUDY00024540||Emano Metrics Accuracy Study|
|Jason Hedges||STUDY00020095||Testicular tissue cryopreservation for fertility preservation in male patients facing infertility-causing diseases or treatment regimens|
Clinical trials at the OHSU Knight Cancer Institute
Clinical trials in women's health
For information on Women's Health Research at OHSU visit the Women's Health Center site, or call our confidential recruitment line: 503-494-3666.